Suchergebnisse - (Subject:"Adalimumab")

PubPharm (208)

11

Nail psoriasis dynamics during biologic treatment and withdrawal in patients with psoriasis who may be at high risk of developing psoriatic arthritis: a post hoc analysis of the VOYAGE 2 randomized trial

in: Arthritis Research & Therapy | 2023

von William Tillett | Alexander Egeberg | Enikö Sonkoly | +5

12

Extracellular matrix turnover biomarkers reflect pharmacodynamic effects and treatment response of adalimumab in patients with axial spondyloarthritis—results from two randomized controlled trials

in: Arthritis Research & Therapy | 2023

von Helena Port | Signe Holm Nielsen | Peder Frederiksen | +8

13

Treatment patterns and clinical outcomes in patients with rheumatoid arthritis initiating etanercept, adalimumab, or Janus kinase inhibitor as first-line therapy: results from the real-world CorEvitas RA Registry

in: Arthritis Research & Therapy | 2023

von Dimitrios A. Pappas | Jacqueline O’Brien | Lin Guo | +5

14

Efficacy and safety of guselkumab and adalimumab for pustulotic arthro-osteitis and their impact on peripheral blood immunophenotypes

enthalten in: Arthritis Research & Therapy | 2022

von Ueno, M. | Miyagawa, I. | Miyazaki, Y. | +5

15

Efficacy and safety of guselkumab and adalimumab for pustulotic arthro-osteitis and their impact on peripheral blood immunophenotypes

enthalten in: Arthritis Research & Therapy | 2022

von Ueno, M. | Miyagawa, I. | Miyazaki, Y. | +5

16

Validation in the ESPOIR cohort of vitamin K-dependent protein S (PROS) as a potential biomarker capable of predicting response to the methotrexate/etanercept combination

enthalten in: Arthritis Research & Therapy | 2022

von Vittecoq, O. | Guillou, C. | Hardouin, J. | +7

17

Validation in the ESPOIR cohort of vitamin K-dependent protein S (PROS) as a potential biomarker capable of predicting response to the methotrexate/etanercept combination

enthalten in: Arthritis Research & Therapy | 2022

von Vittecoq, O. | Guillou, C. | Hardouin, J. | +7

18

Efficacy and safety of guselkumab and adalimumab for pustulotic arthro-osteitis and their impact on peripheral blood immunophenotypes

in: Arthritis Research & Therapy | 2022

von Masanobu Ueno | Ippei Miyagawa | Yusuke Miyazaki | +5

19

Validation in the ESPOIR cohort of vitamin K-dependent protein S (PROS) as a potential biomarker capable of predicting response to the methotrexate/etanercept combination

in: Arthritis Research & Therapy | 2022

von Olivier Vittecoq | Clément Guillou | Julie Hardouin | +7

20

Long-term efficacy, safety, and immunogenicity of the adalimumab biosimilar, PF-06410293, in patients with rheumatoid arthritis after switching from reference adalimumab (Humira®) or continuing biosimilar therapy: week 52–92 data from a randomized, double-blind, phase 3 trial

enthalten in: Arthritis Research & Therapy | 2021

von Fleischmann, R. | Alvarez, D. | Bock, A. | +4